Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis

Matthew C Becker; Thomas H Wang; Lisa Wisniewski; Kathy Wolski; Peter Libby; Thomas F Luscher; Jeffrey S Borer; Alice M Mascette; M Elaine Husni; Daniel H Solomon; David Y Graham; Neville D Yeomans; Henry Krum; Frank Ruschitzka; A Michael Lincoff; Steven E Nissen

doi:10.1016/j.ahj.2008.12.014

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis

Matthew C Becker, Thomas H Wang, Lisa Wisniewski, Kathy Wolski, Peter Libby, Thomas F Luscher, Jeffrey S Borer, Alice M Mascette, M Elaine Husni, Daniel H Solomon, David Y Graham, Neville D Yeomans, Henry Krum, Frank Ruschitzka, A Michael Lincoff, Steven E Nissen

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

106 Citations (Scopus)

Original language	English
Pages (from-to)	606 - 612
Number of pages	7
Journal	American Heart Journal
Volume	157
Issue number	4
DOIs	https://doi.org/10.1016/j.ahj.2008.12.014
Publication status	Published - 2009

Access to Document

10.1016/j.ahj.2008.12.014

Cite this

Becker, M. C., Wang, T. H., Wisniewski, L., Wolski, K., Libby, P., Luscher, T. F., Borer, J. S., Mascette, A. M., Husni, M. E., Solomon, D. H., Graham, D. Y., Yeomans, N. D., Krum, H., Ruschitzka, F., Lincoff, A. M., & Nissen, S. E. (2009). Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal, 157(4), 606 - 612. https://doi.org/10.1016/j.ahj.2008.12.014

Becker, Matthew C ; Wang, Thomas H ; Wisniewski, Lisa et al. / Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. In: American Heart Journal. 2009 ; Vol. 157, No. 4. pp. 606 - 612.

@article{f65efc9b701e4b2d9bf3310e2f813687,

title = "Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis",

author = "Becker, {Matthew C} and Wang, {Thomas H} and Lisa Wisniewski and Kathy Wolski and Peter Libby and Luscher, {Thomas F} and Borer, {Jeffrey S} and Mascette, {Alice M} and Husni, {M Elaine} and Solomon, {Daniel H} and Graham, {David Y} and Yeomans, {Neville D} and Henry Krum and Frank Ruschitzka and Lincoff, {A Michael} and Nissen, {Steven E}",

year = "2009",

doi = "10.1016/j.ahj.2008.12.014",

language = "English",

volume = "157",

pages = "606 -- 612",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby International",

number = "4",

}

Becker, MC, Wang, TH, Wisniewski, L, Wolski, K, Libby, P, Luscher, TF, Borer, JS, Mascette, AM, Husni, ME, Solomon, DH, Graham, DY, Yeomans, ND, Krum, H, Ruschitzka, F, Lincoff, AM & Nissen, SE 2009, 'Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis', American Heart Journal, vol. 157, no. 4, pp. 606 - 612. https://doi.org/10.1016/j.ahj.2008.12.014

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. / Becker, Matthew C; Wang, Thomas H; Wisniewski, Lisa et al.
In: American Heart Journal, Vol. 157, No. 4, 2009, p. 606 - 612.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis

AU - Becker, Matthew C

AU - Wang, Thomas H

AU - Wisniewski, Lisa

AU - Wolski, Kathy

AU - Libby, Peter

AU - Luscher, Thomas F

AU - Borer, Jeffrey S

AU - Mascette, Alice M

AU - Husni, M Elaine

AU - Solomon, Daniel H

AU - Graham, David Y

AU - Yeomans, Neville D

AU - Krum, Henry

AU - Ruschitzka, Frank

AU - Lincoff, A Michael

AU - Nissen, Steven E

PY - 2009

Y1 - 2009

UR - http://www.ncbi.nlm.nih.gov/pubmed/19332185

U2 - 10.1016/j.ahj.2008.12.014

DO - 10.1016/j.ahj.2008.12.014

M3 - Article

SN - 0002-8703

VL - 157

SP - 606

EP - 612

JO - American Heart Journal

JF - American Heart Journal

IS - 4

ER -

Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Luscher TF et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal. 2009;157(4):606 - 612. doi: 10.1016/j.ahj.2008.12.014

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis

Access to Document

Other files and links

Cite this